Biogen is headed for the worst day in a decade after ending trial for blockbuster Alzheimer’s drug.
Shares of Biogen plummeted Thursday after the company halted the trial of Alzheimer's disease drug aducanumab, which it was developing in partnership with Japanese pharmaceutical company Eisai.
The company said in a statement that the decision to stop the phase 3 trial is based on an independent group's analysis showing that the trials were unlikely to"meet their primary endpoint." The recommendation to stop the studies was not based on safety concerns, Biogen said. "This disappointing news confirms the complexity of treating Alzheimer's disease and the need to further advance knowledge in neuroscience," said Michel Vounatsos, chief executive officer of Biogen, in a statement."We are incredibly grateful to all the Alzheimer's disease patients, their families and the investigators who participated in the trials and contributed greatly to this research.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Biogen scraps Alzheimer drug trials, shares slump by a quarterBiogen and partner Eisai Co Ltd are ending two late-stage trials testing the exp...
Consulte Mais informação »
Biogen shares plunge more than 25% after ending trial for Alzheimer's drug Aducanumab
Consulte Mais informação »
Biogen's stock plummets after phase 3 trial of Alzheimer's treatment discontinuedShares of Biogen Inc. plummeted 26% toward a near 3-year low in premarket trade Thursday, after the biotechnology company and Japan's Eisai Co. Ltd. said...
Consulte Mais informação »
Biogen stock plummets 28% after halting Alzheimer’s trialsShares of pharmaceutical giant Biogen Inc. plunged 28% on Thursday morning after the drugmaker said it would discontinue its Phase 3 trials of aducanumab, an...
Consulte Mais informação »
Biogen loses same Alzheimer’s bet others have lostThe failures of similar drugs in formal trials meant Biogen’s effort was always a long shot. Yet ditching it vaporized $18 bln, or over a quarter, of the biotech’s value. The giant market for a therapy and the fear of missing out lured in both the company and Wall Street.
Consulte Mais informação »
Stocks making the biggest moves midday: Levi Strauss, Biogen, Micron & moreThese are the stocks posting the largest moves midday Thursday.
Consulte Mais informação »
Here are the biggest analyst calls of the day: Biogen, Apple, Micron, & moreHere are the biggest calls on Wall Street on Thursday
Consulte Mais informação »
Stocks making the biggest moves premarket: Biogen, Boeing, Walmart, Apple, Clorox & moreSome of the names on the move ahead of the open.
Consulte Mais informação »
Biogen is crashing after scrapping its late-stage Alzheimer's drug trialsBiogen shares crashed more than 25% in pre-market trading after discontinuing two late-stage Alzheimer's drug trials with Eisai.
Consulte Mais informação »
Stocks inch higher, led by AppleStocks fell at the open after the Fed’s latest policy announcement sparked worries about the U.S. economy while shares of Biogen dragged down the health care sector.
Consulte Mais informação »